, marine pharmacology research directed towards the discovery and development of novel anti-tumour agents was published in 163 peer-reviewed articles. The purpose of this review is to present a structured assessment of the anti-tumour and cytotoxic properties of 150 marine natural products, many of which are novel compounds that belong to diverse structural classes, including polyketides, terpenes, steroids and peptides. The organisms yielding these bioactive marine compounds include invertebrate animals, algae, fungi and bacteria. Anti-tumour pharmacological studies were conducted with 31 structurally defined marine natural products in a number of experimental and clinical models that further defined their mechanisms of action. Particularly potent in vitro cytotoxicity data generated with murine and human tumour cell lines was reported for 119 novel marine chemicals with as yet undetermined mechanisms of action. Noteworthy is the fact that marine anti-cancer research was sustained by a global collaborative effort, involving researchers
Introduction
The purpose of this article is to review the 2003-2004 research literature in the field of marine anti-tumour pharmacology, using a format similar to the one used in our previous four reports, which covered 1998-2002. [1] [2] [3] [4] The pharmacology of marine compounds with anthelminthic, anti-bacterial, anticoagulant, anti-diabetic, anti-fungal, anti-inflammatory, anti-malarial, anti-platelet, anti-protozoal, anti-tuberculosis and anti-viral activities; affecting the cardiovascular and nervous systems, and other miscellaneous mechanisms of action have been reviewed elsewhere. [5] [6] [7] [8] Consistent with our previous reviews, only those articles reporting on anti-tumour pharmacology or cytotoxicity of marine compounds with established chemical structures (Figs. 1 and 2) were included in the present review, and are presented in alphabetical order in Tables 1 or 2 . The literature reporting novel information on the preclinical and/or clinical pharmacology of marine chemicals with previously determined mechanisms of action has been summarised in Table 1 discussed briefly in the text of this review. On the other hand, reports on novel marine chemicals which demonstrated significant cytotoxicity but with as yet undetermined mechanisms of action are grouped in Table 2 . With few exceptions, studies on the preclinical anti-tumour pharmacology of synthetic analogues of marine metabolites as well as reports on research with marine extracts or as yet structurally uncharacterised marine chemicals are not included in this review, although several promising studies were published during 2003-2004.
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2003-2004: anti-tumour pharmacology of marine natural products with established mechanisms of action Table 1 summarises novel mechanism of action research from preclinical studies of 31 marine compounds (selected structures are shown in Fig. 1 ). Reports on clinical trials with some of these marine compounds are excluded from Table 1 , but discussed in this section of the article. 1-3 aeroplysinin-1, agosterol A, aplidine, ascididemin, bryostatin-1, dehydrothyrsiferol, didemnin B, dideoxypetrosynol A , dolastatins, ecteinascidin-743, halichondrin B, hemiasterlin, kahalalide F, motuporamines and peloruside. One study extended the preclinical pharmacology of aeroplysinin-1, a compound we reviewed previously. Gonzalez-Iriarte and colleagues 14 developed a modification of the chorioallantoic membrane assay using quail embryos to investigate the anti-angiogenic properties of this marine compound. With this novel assay they demonstrated that the pro-apoptotic properties of aeroplysinin-1 are strong, in particular with proliferating endothelial cells. Two studies were published during 2003-2004 on the preclinical pharmacology of agosterol A, a polyhydroxylated sterol acetate isolated from the marine sponge Spongia sp. Mitsuo and colleagues 15 working with several human epidermoid carcinoma KB cell sub-lines, showed that [I 125 ]-azido agosterol A photolabelled P-glycoprotein (PGP) with high affinity in the absence of glutathione by binding strongly to the N-terminal fragment. The authors suggested that this new photolabelling probe will enable further investigation of the specific residues on P-glycoprotein that are required for agosterol A binding, as well as enhance the therapeutic VEGF is an important mediator of angiogenesis and, although the detailed mechanism by which aplidine inhibits VEGF is currently unknown, the authors noted that VEGF inhibition by an anti-cancer agent had 'never been described before'. Erba and colleagues 18 reported that aplidine had a potent anti-leukaemia effect against human acute lymphoblastic leukaemia cell lines, as well as freshly isolated leukaemia bone marrow samples from 14 patients aged 1-13 years. Aplidine-induced cell death was related to induction of apoptosis with concomitant G 1 arrest and G 2 blockage. Losada and colleagues 19 discovered that C-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinases (p38 MAPK) and concomitant mitochondrial apoptosis was 'slight and transient' in an aplidine-resistant sub-line of human HeLa adenocarcinoma cells they established. These observations suggested that continued activation of these signal transduction enzymes was required for aplidine-triggered apoptosis. Cuadrado and colleagues 20 working with human breast and renal cancer cells, also observed that, at nM concentrations, aplidine induced apoptosis and there was sustained activation of the serine/threonine kinases JNK and p38 MAPK. A possible mechanism might involve aplidine's induction of oxidative stress, leading to a reduction of glutathione levels and activation of the Src tyrosine kinase. Gajate and colleagues 21 noted that aplidine was an extremely rapid and potent apoptosis inducer in leukaemic cells by triggering the Fas/CD95 cell death receptor and concomitant mitochondrial-mediated apoptotic signalling pathways. Because of the rapid and potent apoptosis of leukaemic cells with a concomitant sparing of normal cells in short incubations with aplidine, the authors proposed that the marine natural product might be useful in 'purging approaches to leukaemia treatment'. Taraboletti and colleagues 22 found that aplidine blocked angiogenesis in several in vivo models, while 'at concentrations achievable in patients' plasma' several endothelial cell functions related to angiogenesis were inhibited. Gomez and colleagues 23 using long-term competitive repopulation assays performed in mice determined that doses of aplidine that produced a 
reduction of myeloid progenitors did not appear to affect haematopoietic stem cells. Confirmation of these observations with human haematopoietic stem cell remains to be investigated.
Two preclinical studies contributed during 2003-2004 to the further characterisation of the anti-neoplastic pharmacology of ascididemin, a pyridoacridine alkaloid isolated from the marine sponge Amphimedon sp. Matsumoto and colleagues 24 reported experimental results that suggested direct iminoquinone reduction and reactive oxygen species generation as the probable mechanism responsible for ascididemin cytotoxicity. Dirsch and colleagues 25 investigated the signalling pathways involved in ascididemin-triggered apoptosis in human leukaemia Jurkat T cells. Ascididemin was shown to trigger a mechanism that involved C-Jun N-terminal protein kinase and activation of caspase-2 to induce mitochondrial dysfunction and subsequent apoptotic cell death. Several studies published during 2003-2004 extended the pharmacology of bryostatin-1, a macrocyclic lactone derived from the marine bryozoan, Bugula neritina, which has continued to receive considerable attention in view of its demonstrated anti-neoplastic activity in vitro and in vivo. 
human myeloid leukaemia cell lines. The investigation demonstrated that potentiation of ara-C apoptosis resulted from 'protein kinase C-dependent release of tumour necrosis factor a' and concomitant activation of the extrinsic apoptotic cascade.
One study was reported during 2003 on the preclinical pharmacology of dehydrothyrsiferol (DT), a polyether triterpenoid isolated from a Canary island collection of the red alga Laurencia viridis sp. nov. Pec and colleagues 29 
modified peptides originally isolated from the marine mollusc Dolabella auricularia that induce actin assembly in vivo. Oda and colleagues 32 investigated the molecular mechanism of F-actin stabilisation by dolastatin 11 using X-ray fibre diffraction diagrams. This detailed investigation which revealed that dolastatin 11 localises in the gap region between the two long-pitch strands of F-actin provides a molecular mechanism to explain the observed stabilisation of microfilaments by dolastatin 11. Using the Hummel-Dreyer chromatographic method, Cruz-Monserrate and colleagues 
xenografts derived from different human tumours in nude mice. The results demonstrated that the combination of ET-743 and cisplatin was synergistic both in vitro and in vivo and that both agents could be combined at the maximum tolerated dose perhaps as a result of a lack of overlapping toxicities. The investigators concluded that the results 'provide a strong rationale to undertake investigations on this combination at the clinical level'. Simoens and colleagues 37 determined the in vitro interaction of ET-743 and radiation, and its relation to the cell cycle in four human tumour cell lines. Pre-treatment with ET-743 during 24 h prior to radiation resulted in a moderate increase in radiosensitising properties in 3 out of the 4 cell lines used in the study. Although the investigators determined that the radiosensitivity appeared to be due to a G2/M block, they concluded that further investigation would be necessary to confirm the role of 'cell-cycle effects caused by ET-743' in the mechanism of radiosensitisation which was observed to be cell line-dependent. Shao and colleagues 38 working with a human chondrosarcoma cell line assessed the transcriptional and cellular alterations resulting from resistance to ET-743. They reported that the cell morphology and migratory ability of the ET-743-resistant cell line variant was reduced, and concomitantly there were marked rearrangements of the cytoskeleton architecture which correlated with a decrease of type I collagen a1 chain mRNA in the ET-743-resistance sarcoma cell line. Three studies extended the preclinical in vivo pharmacology of ET-743. Meco with ET-743 in 28 patients with gastrointestinal stromal tumours (GIST), a type of tumour for which there were few alternative therapeutic options prior to the imatinib era. Although the treatment with ET-743 was well tolerated, with only 33% of the patients achieving stable disease as a best response, it was concluded that ET-743 at the dose and schedule used was 'not an effective treatment for advanced GIST'. GarciaCarbonero and colleagues 44 interestingly the rate of disease control of 38.8% at 3 months and 24.1% at 6 months, provided rather encouraging evidence for an anti-tumour effect of ET-743 in this patient population of 'highly pre-treated, progressing, advanced, metastatic, and resistant or refractory sarcoma patients'.
Kuznetsov and colleagues 46 extended the pharmacology of halichondrin B, a large polyether macrolide found in a variety of marine sponges, with a macrocyclic ketone analogue E7389. Investigating human histiocytic lymphoma and prostate cancer cell lines they noted that several morphological and biochemical correlates of apoptosis were clearly observed after prolonged mitotic blockage in the G 2 -M phase of the cell cycle with P10 nM E7389, providing a putative mechanistic basis for the significant in vivo anti-cancer efficacy of this analogue of parental halichondrin B.
With the purpose of contributing to the development of novel anti-microtubule agents that may overcome resistance and have improved pharmacological profiles, Loganzo and colleagues 47 investigated the pharmacology of a synthetic analogue of hemiasterlin, a tripeptide containing three highly modified amino acids isolated from marine sponges. Development of the synthetic hemiasterlin analogue HTI-286 allowed for extensive in vitro studies with 18 human tumour cell lines which demonstrated the analogue potently inhibited proliferation in the nM range, depolymerised microtubules and overcame 'P-glycoprotein-mediated resistance to paclitaxel or vincristine or both in xenograft models and most cell lines that express the protein'. Clinical trials with HTI-286 will be required to determine its clinical utility in cancer treatment.
Suarez and colleagues 48 extended the preclinical pharmacology of kahalalide F, a naturally occurring depsipeptide isolated from the Hawaiian herbivorous marine mollusc Elysia rufescen and currently under clinical investigation. Kahalalide F resulted in potent loss of mitochondrial membrane potential, lysosomal integrity, as well as cytotoxicity against human prostate and breast cancer cell lines at an IC 50 < 0.3 lM. There was concomitant rapid and severe cytoplasmatic swelling and vacuolisation, but with no caspase activity or alteration of nuclear structure. The investigators concluded that kahalalide F induced cell death by a non-apoptotic mode of action termed oncosis, a process involving a 'progression of cellular events leading to necrotic cell death'. Novel preclinical pharmacology of the anti-invasion and anti-angiogenic alkaloids motuporamines, isolated from the [54] (continued on next page) 58 continued studies on the extracellular acidic polysaccharide GA3P, a D-galactan sulphate associated with L-(+)-lactic acid produced by the marine microalga Gymnodinium sp. GA3P was shown to be a potent inhibitor of topoisomerases I and II, a process that did not involve accumulation of DNA-topoisomerase I/II cleavable complexes, suggesting that this polysaccharide is a catalytic inhibitor with dual activity and high affinity. Furthermore, GA3P exhibited significant in vitro cytotoxicity against 39 human tumours (range 0.67-11 lg/ml).
With the purpose of continuing the development of compounds that inhibit the G 2 checkpoint as potentially valuable agents for enhancing the effectiveness of DNA-damaging agents in tumours with mutated p53, Jian and colleagues 59 published a detailed study on the molecular pharmacology of the marine alkaloid isogranulatimide, originally isolated from the Brazilian ascidian Didemnum granulatum. Using natural and synthetic isogranulatimide analogues the investigators demonstrated that the imide and basic nitrogen at position 14 or 15 in the imidazole ring were requirements for G 2 checkpoint inhibition, and that concomitant inhibition of the DNA damage response Chk1 protein kinase (IC 50 = 0.1 lM) played an important role in the process. By X-ray crystallography the authors determined the structural elements required for isogranulatimide activity as a Chk1 kinase inhibitor, and concluded that this agent may be a 'promising candidate for modulating checkpoint responses in tumours'.
With the purpose of contributing to the search for noncamptothecin topoisomerase I poisons, Facompre and colleagues 60 found that the hexacyclic marine alkaloid lamellarin D, isolated from the mollusc Lamellaria sp. was a potent inhibitor of DNA topoisomerase I. The pharmacological properties of lamellarin D and LAM-501, a synthetic lamellarin derivative, were compared with those of camptothecin, from which topotecan and irinotecan have been derived for treatment of metastatic ovarian and colon cancers. The results of this investigation collectively identify lamellarin D as low-affinity DNA intercalator yet a potent inhibitor of the DNA/cleavage activity of topoisomerase I, which interacts differently with the topoisomerase I-DNA interface than camptothecin, and which 'should be considered as a new pharmacophore for topoisomerase I targeting '. The development of novel marine agents to target hypoxic tumour cells' induction of the transcription factor hypoxiainducible factor-1 (HIF-1) gene expression that is associated with poor prognosis and treatment resistance was investigated by Mohammed and colleagues. 61 Using a human breast tumour cell-based reporter assay and bioassay-guided fractionation these investigators isolated a novel diterpene laurenditerpenol in the red alga Laurencia intricata which inhibited HIF-1 (IC 50 = 0.4 lM) probably as a result of blocking the induction of nuclear HIF-1a protein. 63 extended the molecular pharmacology of neoamphimedine, a pyridoacridine isomer of amphimedine which was isolated from the Philippine marine sponge Xestospongia sp. Low concentrations of neoamphimedine induced catenation of plasmid DNA in the presence of active topoisomerase IIa (top2), which correlated with DNA aggregation. Interestingly, neoamphimedine but not amphimedine, showed potent anti-tumour activity in athymic mice bearing human KB tumours, which was equivalent to etoposide, thus suggesting that this marine compound has 'a novel top2-mediated mechanism of toxicity and anticancer potential'. Two papers extended the pharmacology of the marine bromotyrosine derivative psammaplin A, isolated from a twosponge association between, Poecillastra sp. and Jaspis sp. Shim and colleagues 64 showed that psammaplin A inhibited aminopeptidase N (APN) (IC 50 = 18 lM) in a non-competitive manner, a finding of considerable interest because APN is an enzyme that is crucial for angiogenesis, a process involved in both in tumour cell growth and metastasis. The authors concluded that psammaplin A's inhibition of APN activity suggests a potentially novel approach to prevent angiogenesis-related diseases. Furthermore, Jian and colleagues 65 noted that psammaplin A inhibited SV40 DNA replication in vitro by inhibiting the DNA polymerase a-primase complex.
With the purpose of contributing to the search for new differentiation-inducing agents for haematopoietic cancer, Aoki and colleagues 66 investigated the marine sesquiterpene aminoquinone smenospongine isolated from the Indonesian marine sponge Dactylospongia elegans. Smenospongine increased haemoglobin production in human chronic myelogenous leukaemia (CML) cells, with concomitant increased expression of glycophorin A, a marker for erythroid differentiation. Furthermore the marine compound induced cell cycle arrest at G 1 phase probably due to increased expression of p21, while also inhibiting Crkl phosphorylation, a substrate of the Bcr-Abl tyrosine kinase known to be involved in CML pathogenesis. The authors conclude that smenospongine 'is expected to be a promising candidate for treatment of CML'.
2003-2004
: anti-tumour pharmacology of marine natural products with undetermined mechanisms of action 50 of < = 1.0 lg/ml) and structures are shown in Fig. 2 . The preclinical pharmacology completed with these marine compounds consisted mainly of in vitro and/or in vivo cytotoxicity testing with panels of either human or murine tumour cell lines. In a few reports cytotoxicity studies were more extensive and included the National Cancer Institute (NCI) 60-tumour cell line screen. It is clear that additional pharmacological testing will be required to help determine if the potent cytotoxicity observed with these marine chemicals resulted from a pharmacological rather than a simple toxic effect on the tumour cells used in these investigations. Although contrasting with the extensive preclinical and clinical investigation completed with the marine compounds presented in Table 1 , mechanism of action research was reported for several of the marine compounds listed in Although less potent than the marine natural products included in Table 2 , 30 additional reports were published during 2003-2004 describing novel structurally characterised molecules with cytotoxic activity (IC 50 ) mostly in the >1-4.0 lg/ml range. Although only the cytotoxicity against selected murine or human cancer cells was determined in vitro in the majority of these reports, mechanistic work was reported in a few studies, e.g. induction of erythroid differentiation in human leukaemia by 5-epi-smenospongorine. 
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